Market Intelligence, Preclinical Progress, and High-Purity Reagents for Lipid Metabolism, Autophagy, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BLTP2/KIAA0100 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BLTP2/KIAA0100 Recombinant Protein (Full-Length & Domain Fragments) – High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View BLTP2 Products |
| Gene Delivery | BLTP2/KIAA0100 Promise-ORF / Lentivirus – Full-length ORF for stable cell line generation. CMV promoter. | View BLTP2 Products |
| Benchmark Ab | Anti-BLTP2/KIAA0100 Recombinant Monoclonal Antibody – Recombinant positive control for ELISA, Western blot, and IHC. Sequence Verified. | View BLTP2 Products |
| Validator | BLTP2/KIAA0100 siRNA Set – Three unique sequences for knockdown verification and specificity controls. | View BLTP2 Products |
| Related Target: CETP | Cholesteryl Ester Transfer Protein – Synergistic lipid metabolism pathway; same BPI-fold superfamily. Selectivity counter-screening. | View CETP Products |
| Related Target: BPI | Bactericidal/Permeability-Increasing Protein – Family prototype sharing lipid transfer mechanism; comparative binding studies. | View BPI Products |
| Related Target: EGFR | Epidermal Growth Factor Receptor – Crucial oncogenic pathway node often co-activated in aggressive breast cancers. | View EGFR Products |
| Related Target: CD274 (PD-L1) | Programmed Death-Ligand 1 – Key checkpoint for immuno-oncology combination strategies. | View CD274 Products |
| Related Target: LC3B (MAP1LC3B) | Core autophagy pathway partner; critical for LIR-motif binding assays. | View MAP1LC3B Products |
| Related Target: p62 (SQSTM1) | Autophagy cargo receptor; synergistic pathway for flux analysis. | View SQSTM1 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Lipid Binding Validation (BODIPY-Cholesterol/Phospholipid transfer) | High-purity (>95%) recombinant BLTP2 with native BPI-fold conformation; Endotoxin <1 EU/μg for sensitive cellular uptake assays. Theoretical MW confirmed by Mass Spec. |
| Cross-species Cyno/Mouse Ortholog Evaluation | Human/Mouse/Cynomolgus BLTP2 ortholog proteins available with >95% purity; Sequence verified for preclinical toxicology translation. |
| Autophagy Flux Quantification | Compatible with LC3-II co-detection; BLTP2 lentivirus for stable overexpression in HEK293/HeLa with puromycin selection. |
| Large Multi-domain Protein Expression (>200 kDa) | Multiple domain fragments (N-term, CC, C-term) available at >95% purity; Sequence Verified to overcome aggregation. |
| False Positives in Lipid Transfer Assays | Validated siRNA included for specificity checks; Negative control protein (mutant BPI-fold domain) available for assay standardization. |
| Subfamily Selectivity (vs BPI/CETP/PLTP) | Homolog panel proteins strictly verified by Mass Spec for counter-screening assays. |
Live BLTP2/KIAA0100 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (KIAA0100)
- ➤ View Active Clinical Trials (BLTP2)
- ➤ Latest Lipid Transfer Research
- ➤ Latest Autophagy Research
- ➤ Recent Patent Filings
- ➤ Latest TNBC Resistance Research
Global Clinical Landscape & Future Outlook
BLTP2 (KIAA0100) represents an emerging therapeutic node at the intersection of lipid metabolism, autophagy, and oncology. Initially identified as a large coiled-coil protein, it has been characterized as a Bridge-like lipid transfer protein belonging to the BPI-fold superfamily. Recent high-throughput proteomics have identified BLTP2 as a prognostic biomarker in triple-negative breast cancer (TNBC) and glioblastoma. The target is currently in preclinical validation across most indications, with no Phase II/III candidates yet disclosed. The next wave of R&D is concentrating on mapping its LC3-interacting region (LIR) motif and elucidating its precise function in oncogenic survival pathways. Major academic and early biotech players are shifting focus toward small molecule inhibitors (targeting the lipid-binding pocket), targeted protein degraders (PROTACs), and RNAi-based therapies. As the mechanistic link between BLTP2-mediated lipid transport and autophagosome maturation clarifies, increased investment in combination regimens with PI3K/mTOR inhibitors or immune checkpoint blockade is expected.
Competitive Modality & Indication Snapshot
| Modality | Development Stage | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Hit-to-Lead | NAFLD/NASH, Solid Tumors (TNBC, Glioma) | Biochemical Binding Assay (Need high-purity recombinant BLTP2 with native BPI-fold conformation) |
| Neutralizing Antibody | Early Discovery | Breast Cancer, Glioma | Epitope Mapping (Need full-length vs domain-specific antigens; BLTP2 stability testing) |
| siRNA/ASO | Preclinical | Metabolic Syndrome, Oncology | Phenotypic Screening (Need validated siRNA sets and lentiviral constructs) |
| PROTAC / Degraders | Emerging Programs | Metastatic Breast Cancer, Solid Tumors | Degradation Validation (Need specific benchmark antibodies and mutant proteins) |
| Autophagy Modulators | Translational Research | Neurodegeneration, Cancer | PPI Disruption (Need LC3 co-reagents & cell-based flux assays) |
Known Genetic Variants
Based on UniProt entry Q14667 (BLTP2), the following validated single nucleotide polymorphisms have been reported:
- rs16964472 (VAR_027352)
- rs12602520 (VAR_027353)
- rs16964462 (VAR_052706)
These variants may affect protein structure or function and should be considered when designing allele-specific assays or interpreting patient stratification data.